GEN3014 DP, DARZALEX 1800 mg solution for injection
GCT3014-01
Phase 2 small_molecule active
Quick answer
GEN3014 DP, DARZALEX 1800 mg solution for injection for Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Genmab A/S
- Indication
- Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active